# Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

> **NCT01474421** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 71 (actual)

## Conditions studied

- Dyskinesias
- Drug-induced

## Interventions

- **DRUG:** AQW051
- **DRUG:** AQW051
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01474421
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-15
- **Primary completion:** 2013-02-21
- **Final completion:** 2013-02-21
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474421, "Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT01474421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*